Iovance Biotherapeutics, Inc.
Clinical trials sponsored by Iovance Biotherapeutics, Inc., explained in plain language.
A biopharmaceutical company developing tumor-infiltrating lymphocyte (TIL) therapies for cancer.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Gene-Hacked immune cells take on tough cancers Results expected Sep 2027 (estimated)
-
Personalized cell therapy shows promise for tough cervical cancers
Disease control Stopped earlyThis phase 2 study tested a personalized treatment called LN-145 for women with recurrent or advanced cervical cancer. The therapy uses a patient's own tumor-fighting immune cells, grown in a lab and infused back. The trial aimed to see if it could shrink tumors, but it was termi…
Phase 2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Personalized cell therapy shows promise but trial ends early
Disease control Stopped earlyThis study tested a personalized treatment using immune cells taken from a patient's own tumor, called tumor-infiltrating lymphocytes (TIL). The cells were grown in a lab and given back to the patient to fight their cancer. The trial included people with advanced melanoma, head a…
Phase 2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC